DE69535253D1 - Humanisierte antikörper gegen das respiratorische syncytialvirus - Google Patents

Humanisierte antikörper gegen das respiratorische syncytialvirus

Info

Publication number
DE69535253D1
DE69535253D1 DE69535253T DE69535253T DE69535253D1 DE 69535253 D1 DE69535253 D1 DE 69535253D1 DE 69535253 T DE69535253 T DE 69535253T DE 69535253 T DE69535253 T DE 69535253T DE 69535253 D1 DE69535253 D1 DE 69535253D1
Authority
DE
Germany
Prior art keywords
humanized antibodies
syncytialvirus
respiratory
respiratory syncytialvirus
mab1129
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69535253T
Other languages
English (en)
Other versions
DE69535253T2 (de
Inventor
Leslie Syd Johnson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Publication of DE69535253D1 publication Critical patent/DE69535253D1/de
Application granted granted Critical
Publication of DE69535253T2 publication Critical patent/DE69535253T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
DE69535253T 1994-08-15 1995-08-09 Humanisierte antikörper gegen das respiratorische syncytialvirus Expired - Lifetime DE69535253T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US290592 1994-08-15
US08/290,592 US5824307A (en) 1991-12-23 1994-08-15 Human-murine chimeric antibodies against respiratory syncytial virus
PCT/US1995/010053 WO1996005229A1 (en) 1994-08-15 1995-08-09 Human-murine chimeric antibodies against respiratory syncytial virus

Publications (2)

Publication Number Publication Date
DE69535253D1 true DE69535253D1 (de) 2006-11-16
DE69535253T2 DE69535253T2 (de) 2007-05-16

Family

ID=23116697

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69535253T Expired - Lifetime DE69535253T2 (de) 1994-08-15 1995-08-09 Humanisierte antikörper gegen das respiratorische syncytialvirus

Country Status (11)

Country Link
US (4) US5824307A (de)
EP (3) EP1659133B1 (de)
JP (6) JP3896160B2 (de)
AT (1) ATE341563T1 (de)
AU (1) AU713113B2 (de)
CA (1) CA2197684C (de)
DE (1) DE69535253T2 (de)
DK (2) DK0783525T3 (de)
ES (2) ES2442460T3 (de)
PT (2) PT783525E (de)
WO (1) WO1996005229A1 (de)

Families Citing this family (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US20020102257A1 (en) * 1998-09-21 2002-08-01 Leslie Sid Johnson Human-murine chimeric antibodies against respiratory syncytial virus
US5824307A (en) * 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
US6685942B1 (en) 1993-12-10 2004-02-03 The Scripps Research Institute Human neutralizing monoclonal antibodies to respiratory syncytial virus
US20050002867A1 (en) * 1997-10-01 2005-01-06 Novadel Pharma Inc. Buccal, polar and non-polar sprays containing propofol
US20030185761A1 (en) * 1997-10-01 2003-10-02 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US20030095925A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
US20040136913A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing sumatriptan
US20030190286A1 (en) * 1997-10-01 2003-10-09 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma
US20030095926A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
US20050163719A1 (en) * 1997-10-01 2005-07-28 Dugger Harry A.Iii Buccal, polar and non-polar spray containing diazepam
AU4894697A (en) * 1997-10-01 1999-04-23 Flemington Pharmaceutical Corporation Buccal, polar and non-polar spray or capsule
US20050281752A1 (en) * 1997-10-01 2005-12-22 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20040136914A1 (en) 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing ondansetron
US20090162300A1 (en) * 1997-10-01 2009-06-25 Dugger Iii Harry A Buccal, polar and non-polar spray containing alprazolam
US7632517B2 (en) * 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
US20030077228A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating endocrine disorders
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20030095927A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders
US20050287075A1 (en) * 1997-10-01 2005-12-29 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US20040141923A1 (en) * 1997-10-01 2004-07-22 Dugger Harry A. Buccal, polar and non-polar spray containing alprazolam
US20030077229A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
US20040136915A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing atropine
US20050180923A1 (en) * 1997-10-01 2005-08-18 Dugger Harry A.Iii Buccal, polar and non-polar spray containing testosterone
US20030082107A1 (en) * 1997-10-01 2003-05-01 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer
WO1999045959A1 (en) * 1998-03-13 1999-09-16 Dana-Farber Cancer Institute, Inc. Humanized antibody and uses thereof
AR030019A1 (es) * 1999-05-18 2003-08-13 Smithkline Beecham Corp Anticuerpos monoclonales humanos y fragmentos funcionales del mismo, un procedimiento para su produccion, composiciones farmaceuticas que los comprenden, una molecula aislada de acido nucleico, un plasmido recombinante, una celula hospedante y el uso de dichos anticuerpos para la manufactura de un m
AU2001240020B9 (en) 2000-03-01 2008-12-04 Medimmune, Llc High potency recombinant antibodies and method for producing them
DK1265928T3 (da) 2000-01-27 2010-11-15 Medimmune Llc RSV-neutraliserende antistoffer med ultra høj affinitet
US7229619B1 (en) * 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
WO2001059142A1 (en) * 2000-02-09 2001-08-16 Medimmune, Inc. Antibody gene therapy with adeno-associated viral vectors
US6565849B2 (en) 2000-03-02 2003-05-20 Medimmune, Inc. Methods of enhancing activity of vaccines and vaccine compositions
WO2001082965A1 (en) * 2000-05-03 2001-11-08 Medimmune, Inc. Combination therapy of respiratory diseases using antibodies
JP2003531867A (ja) * 2000-05-03 2003-10-28 メディミューン，インコーポレイテッド 抗体および抗炎症薬を用いた呼吸器疾患の組合せ治療法
AU2008202076B2 (en) * 2000-11-28 2011-09-08 Medimmune, Llc Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6818216B2 (en) 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
TWI327599B (en) * 2000-11-28 2010-07-21 Medimmune Llc Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7179900B2 (en) * 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US7658921B2 (en) * 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
NZ555567A (en) * 2001-01-19 2008-07-31 Vironovative Bv A virus causing respiratory tract illness in susceptible mammals
US20030232061A1 (en) * 2001-10-18 2003-12-18 Fouchier Ronaldus Adrianus Maria Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
US8715922B2 (en) * 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
GB2378949B (en) * 2001-08-16 2005-09-07 Morten Steen Hanefeld Dziegiel Recombinant anti-plasmodium falciparum antibodies
TWI405851B (zh) 2002-02-21 2013-08-21 Medimmune Llc 間質肺病毒株及其作為疫苗調配物及作為表現抗原性序列之載體之應用
CN101143221A (zh) * 2002-03-15 2008-03-19 布赖汉姆妇女医院 适合治疗剂全身性递送的中央气道给药
US20040063912A1 (en) * 2002-03-15 2004-04-01 The Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics
EP2270049A3 (de) 2002-04-12 2011-03-09 Medimmune, Inc. Rekombinante Anti-Interleukin-9-Antikörper
US20050152899A1 (en) * 2002-05-10 2005-07-14 Kinch Michael S. EphA2 agonistic monoclonal antibodies and methods of use thereof
CA2485548A1 (en) * 2002-05-10 2004-02-19 Purdue Research Foundation Epha2 agonistic monoclonal antibodies and methods of use thereof
WO2003094859A2 (en) * 2002-05-10 2003-11-20 Medimmune, Inc. Epha2 monoclonal antibodies and methods of use thereof
AU2013201261B2 (en) * 2002-06-14 2016-06-23 Medimmune, Llc Stabilized liquid anti-RSV antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) * 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
TW200501985A (en) * 2002-07-25 2005-01-16 Medimmune Inc Methods of treating and preventing RSV, hMPV, and PIV using anti-RSV, anti-hMPV, and anti-PIV antibodies
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
ES2543630T3 (es) 2003-04-01 2015-08-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticuerpos dirigidos contra el complejo E1E2 del virus de la hepatitis C y sus epítopos
EP1617864A4 (de) * 2003-04-11 2006-06-21 Medimmune Inc Epha2 und nicht-neoplastische hyperproliferative zellstörungen
KR20110094361A (ko) * 2003-04-11 2011-08-23 메디뮨 엘엘씨 재조합 ｉｌ­９ 항체 및 그의 용도
WO2004092343A2 (en) * 2003-04-11 2004-10-28 Medimmune, Inc. Epha2, hypoproliferative cell disorders and epithelial and endothelial reconstitution
WO2005027825A2 (en) * 2003-04-25 2005-03-31 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
EP2494987A1 (de) 2003-04-25 2012-09-05 MedImmune Vaccines, Inc. Metapneumovirusstämme und deren Verwendung in Impfstoffformulierungen und als Vektoren für die Expression antigener Sequenzen und Verfahren zur Ausbreitung des Virus
WO2005060520A2 (en) * 2003-11-25 2005-07-07 Dana-Farber Cancer Institute, Inc. ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF
EP1720908A2 (de) * 2004-02-17 2006-11-15 Absalus, Inc. Superhumanisierte antikörper gegen respiratory syncytial virus
EP2168986A3 (de) * 2004-02-19 2010-07-28 Genentech, Inc. Antikörper mit korrigiertem CDR
EP1755673B1 (de) 2004-04-12 2014-07-23 MedImmune, LLC Anti-il-9-antikörperformulierungen und deren verwendung
US7700720B2 (en) * 2004-09-21 2010-04-20 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
US7910101B2 (en) 2004-10-25 2011-03-22 Centocor, Inc. Melanocortin receptor binding mimetibodies, compositions, methods and uses
TW200636064A (en) * 2004-10-28 2006-10-16 Centocor Inc Anti-respiratory syncytial virus antibodies, antigens and uses thereof
EP1812068A4 (de) * 2004-10-29 2010-06-09 Medimmune Inc Verfahren zur prävention und behandlung von rsv-infektionen und verwandten leiden
US20060216700A1 (en) * 2005-03-10 2006-09-28 Medimmune Vaccines, Inc. Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
CA2603940A1 (en) * 2005-04-08 2006-10-19 Nancy Ulbrandt Antibodies against mammalian metapneumovirus
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
US20090220527A1 (en) * 2005-12-21 2009-09-03 Medlmmune, Llc Affinity optimized epha2 agonistic antibodies and methods of use thereof
BRPI0708636A2 (pt) * 2006-03-06 2011-06-07 Symphogen As anticorpo policlonal recombinante para tratamento de infecções por vìrus sinciciais respiratórios
CA2649895C (en) * 2006-04-19 2013-03-26 Novadel Pharma Inc. Stable hydroalcoholic oral spray formulations and methods
BRPI0713426A2 (pt) 2006-06-14 2012-10-09 Macrogenics Inc métodos de tratar, diminuir a progressão, ou melhorar um ou mais sintomas de um distúrbio, e de prevenir ou retardar o inìcio de um distúrbio
KR101314362B1 (ko) 2006-08-28 2013-10-10 라 졸라 인스티튜트 포 앨러지 앤드 이뮤놀로지 길항성 인간 ｌｉｇｈｔ-특이적 인간 모노클로날 항체
WO2008079295A1 (en) * 2006-12-22 2008-07-03 Novadel Pharma Inc. Stable anti-nausea oral spray formulations and methods
MX2009009226A (es) * 2007-03-06 2009-10-28 Symphogen As Anticuerpos recombinantes para el tratamiento de infecciones con el virus respiratorio sincitial.
CN101668771B (zh) 2007-03-12 2013-08-21 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 单链抗体的基于序列的工程改造和最优化
EP2152304B1 (de) 2007-05-02 2018-08-22 The Regents of the University of Michigan Therapeutische zusammensetzungen in nanoemulsionsform und anwendungsverfahren dafür
BRPI0811430A2 (pt) * 2007-05-10 2015-06-23 Novadel Pharma Inc Composições anti-insônia e processos
EP1997830A1 (de) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV-spezifische Bindemoleküle und Mittel zu ihrer Herstellung
PT2164961E (pt) * 2007-06-25 2015-04-08 Esbatech Alcon Biomed Res Unit Manipulação baseada em sequências e otimização de anticorpos de cadeia única
JP5611820B2 (ja) * 2007-06-25 2014-10-22 エスバテック − ア ノバルティスカンパニー エルエルシー 抗体の修飾方法並びに改善された機能特性を有する修飾された抗体
US7867497B2 (en) * 2007-09-24 2011-01-11 Vanderbilt University Monoclonal antibodies to respiratory syncytial virus and uses therefor
US20090186050A1 (en) * 2007-11-16 2009-07-23 Fouchier Ron A M Live attenuated metapneumovirus strains and their use in vaccine formulations and chimeric metapneumovirus strains
EP2285408B1 (de) * 2008-06-05 2018-10-24 Ablynx N.V. Gegen hüllproteine eines virus gerichtete aminosäuresequenzen und diese enthaltende polypeptide zur behandlung von viruserkrankungen
CA2728829C (en) 2008-06-25 2018-01-02 Esbatech, An Alcon Biomedical Research Unit Llc Solubility optimization of immunobinders
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
WO2010068722A1 (en) 2008-12-12 2010-06-17 Medimmune, Llc Crystals and structure of a human igg fc variant with enhanced fcrn binding
US8852608B2 (en) 2009-02-02 2014-10-07 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
ES2553440T3 (es) * 2009-08-13 2015-12-09 Crucell Holland B.V. Anticuerpos contra el virus sincitial respiratorio humano (VSR) y método de uso
WO2011020024A2 (en) 2009-08-13 2011-02-17 The Johns Hopkins University Methods of modulating immune function
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
AR082149A1 (es) * 2010-07-09 2012-11-14 Calmune Corp Anticuerpos contra el virus sincicial respiratorio (rsv) humano y metodos para su uso
US9320793B2 (en) * 2010-07-14 2016-04-26 Acumen Pharmaceuticals, Inc. Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP4108671A1 (de) 2010-10-01 2022-12-28 ModernaTX, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und ihre verwendungen
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CN103974724B (zh) 2011-10-03 2019-08-30 现代泰克斯公司 修饰的核苷、核苷酸和核酸及其用途
CN104203982B (zh) 2011-10-28 2018-08-31 特瓦制药澳大利亚私人有限公司 多肽构建体及其用途
CA2859387A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
AU2013243951A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
JP6144355B2 (ja) 2012-11-26 2017-06-07 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 化学修飾ｍＲＮＡ
TWI659968B (zh) 2013-03-14 2019-05-21 再生元醫藥公司 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法
US9649375B2 (en) 2013-03-14 2017-05-16 The Administrators Of The Tulane Educational Fund Immunogenic peptide conjugate and method for inducing an anti-influenza therapeutic antibody response therewith
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
SG11201509982UA (de) 2013-06-06 2016-04-28 Igenica Biotherapeutics Inc
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EA201690675A1 (ru) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
BE1022441B1 (fr) * 2014-02-10 2016-03-30 Univercells Sa Systeme, appareil et procede pour production de biomolecules
AU2015213593B2 (en) 2014-02-10 2020-09-03 Igm Biosciences, Inc. IgA multi-specific binding molecules
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9340604B1 (en) * 2014-10-29 2016-05-17 Aridis Pharmaceuticals, Inc. Human monoclonal antibody specific for the F protein of respiratory syncytial virus (RSV)
CN107108054B (zh) 2014-10-31 2020-10-13 免疫医疗有限责任公司 改进的制造方法
PT3333191T (pt) 2014-12-11 2020-12-15 Pf Medicament Anticorpos anti-c10orf54 e suas utilizações
PL3265123T3 (pl) 2015-03-03 2023-03-13 Kymab Limited Przeciwciała, zastosowania i sposoby
CL2015002152A1 (es) 2015-07-31 2016-06-03 Pontificia Universidad Católica De Chile Anticuerpos monoclonales específicos para el antígeno p del virus respiratorio sincicial humano (vrsh), producidos y secretados por hibridomas celulares, útiles para la detección y el diagnostico de la infección causada por vrsh
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
AU2017345759A1 (en) 2016-10-21 2019-05-23 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
JP2020503843A (ja) 2016-10-21 2020-02-06 アディマブ， エルエルシー 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法
US11479600B2 (en) 2016-10-21 2022-10-25 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
WO2020016459A1 (en) 2018-07-20 2020-01-23 Pierre Fabre Medicament Receptor for vista
WO2021005232A1 (en) 2019-07-11 2021-01-14 Umc Utrecht Holding B.V. Intranasal administration of neutralising antiviral antibodies
WO2021202463A1 (en) 2020-03-30 2021-10-07 Danisco Us Inc Anti-rsv antibodies

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0043272B1 (de) * 1980-07-01 1984-06-13 National Research Development Corporation Herstellung von Virusantigenen
US4717766A (en) * 1986-01-27 1988-01-05 Miles Laboratories, Inc. Method of preparing high titer anti-respiratory syncytial virus intravenous immune globulin
US4659563A (en) * 1986-01-27 1987-04-21 Miles Laboratories, Inc. High titer anti-respiratory syncytial virus intravenous immune globulin
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4800078A (en) * 1987-05-28 1989-01-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunotherapeutic method of treating respiratory disease by intranasal administration of Igb
GB8720833D0 (en) * 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5223254A (en) * 1987-09-29 1993-06-29 Praxis Biologics, Inc. Respiratory syncytial virus: vaccines
DE3878468T2 (de) * 1987-12-23 1993-06-09 Upjohn Co Chimarenglykoproteine, enthaltend immunogene segmente des humanen respiratorischen synzytialvirus.
WO1989007142A1 (en) 1988-02-05 1989-08-10 Morrison Sherie L Domain-modified constant region antibodies
US5183657A (en) * 1988-03-11 1993-02-02 Celltech Limited Antibodies for use in antilymphocyte antibody therapy
JP2919890B2 (ja) 1988-11-11 1999-07-19 メディカル リサーチ カウンスル 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5332567A (en) * 1989-08-24 1994-07-26 Immunomedics Detection and treatment of infections with immunoconjugates
GB9019812D0 (en) * 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
GB9020282D0 (en) 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
CA2109528A1 (en) * 1991-05-01 1992-11-02 Gregory A. Prince A method for treating infectious respiratory diseases
WO1993005796A1 (en) 1991-09-19 1993-04-01 The Scripps Research Institute Method for producing human antibodies in a non-human animal, and animals therefor
US5240694A (en) * 1991-09-23 1993-08-31 University Of Virginia Combined antiviral and antimediator treatment of common colds
US5824307A (en) 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
US20020102257A1 (en) * 1998-09-21 2002-08-01 Leslie Sid Johnson Human-murine chimeric antibodies against respiratory syncytial virus
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2686901A1 (fr) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
AU3923293A (en) 1992-03-20 1993-10-21 Immunet Human monoclonal antibodies and methods for human monoclonal antibody production
GB9207479D0 (en) 1992-04-06 1992-05-20 Scotgen Ltd Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man
ES2191016T3 (es) 1992-09-16 2003-09-01 Scripps Research Inst Anticuerpos monoclonales neutralizantes humanos para el virus respiratorio sincitial.
AU3660893A (en) * 1993-01-29 1994-08-15 Med Immune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US6818216B2 (en) * 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies

Also Published As

Publication number Publication date
EP1659133A2 (de) 2006-05-24
EP1659133A3 (de) 2009-01-21
ES2442460T3 (es) 2014-02-11
PT1659133E (pt) 2014-01-20
JP2006265263A (ja) 2006-10-05
EP1659133B1 (de) 2013-10-16
US7704505B2 (en) 2010-04-27
JPH10504195A (ja) 1998-04-28
JP2009029817A (ja) 2009-02-12
JP3896160B2 (ja) 2007-03-22
DK1659133T3 (da) 2014-01-27
US20120156195A1 (en) 2012-06-21
JP2012207022A (ja) 2012-10-25
US5824307A (en) 1998-10-20
CA2197684C (en) 2000-10-31
JP2008024707A (ja) 2008-02-07
EP2371858A2 (de) 2011-10-05
ATE341563T1 (de) 2006-10-15
PT783525E (pt) 2007-01-31
AU3215895A (en) 1996-03-07
JP2010241819A (ja) 2010-10-28
DK0783525T3 (da) 2007-02-05
WO1996005229A1 (en) 1996-02-22
EP0783525A4 (de) 2000-08-30
JP4216297B2 (ja) 2009-01-28
EP0783525A1 (de) 1997-07-16
EP2371858A3 (de) 2011-10-26
US20090104205A1 (en) 2009-04-23
CA2197684A1 (en) 1996-02-22
US20140093501A1 (en) 2014-04-03
ES2274518T3 (es) 2007-05-16
EP0783525B1 (de) 2006-10-04
AU713113B2 (en) 1999-11-25
US8562994B2 (en) 2013-10-22
DE69535253T2 (de) 2007-05-16

Similar Documents

Publication Publication Date Title
ATE341563T1 (de) Humanisierte antikörper gegen das respiratorische syncytialvirus
NO20001671D0 (no) Naturlige humaniserte antistoff
ATE512224T1 (de) Rekonstituierter menschlicher anti-hm.1 antikörper
DE69535133D1 (de) Humanisierte antikörper gegen das leukozytenadhäsionsmolekül vla-4
UA111707C2 (uk) Застосування виділеного анти-tnf-альфа антитіла людини
ATE231002T1 (de) Menschliche, neutralisierende, monoklonale antikörper gegen das respiratorische synzytialvirus
FR12C0004I1 (de)
DK1140170T3 (da) Antistoffragmenter til topisk behandling af öjensygdomme
NO985200L (no) Antimikrobiell behandling for herpes simplex virus, og andre infeksi÷se syk
CA2192512A1 (en) Nm03 antibody materials and methods
ATE495751T1 (de) Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
MX9301858A (es) Anticuerpos monoclonales neutralizantes de hiv-humano recombinante para prevencion y tratamiento de infeccion hiv.
DE69129582T2 (de) Antikörper gegen menschlichen plasmin-alpha 2-plasmininhibitor-komplex, hybridoma und immunoassay
EP0450573A3 (de) Antikörper für die Behandlung und die Diagnose von Pseudomonas aeruginosa Infektionen
DE59310204D1 (de) Spezifische Antikörper gegen aktivierte Plättchen, ihre Herstellung und ihre Verwendung in Diagnose und Therapie
DK0470989T3 (da) Anvendelse af monoklonale anti-beta2 mikroglobulin antistoffer
CA2079230A1 (en) Bcrf1 antagonists for treating epstein-barr virus infections
DE69231058T2 (de) Hochaffine humanisierte monoklonale antikoerper
DE29512719U1 (de) Monoklonale Antikörper gegen humanes Interleukin-10
RU93035807A (ru) Способ лечения юношеского эпифизиолиса

Legal Events

Date Code Title Description
8364 No opposition during term of opposition